Our findings suggest a role for siRNA-mediated gremlin inhibition in protecting the kidney from the development and progression of diabetic nephropathy, and support the further study of Gremlin as a therapeutic target in the treatment of DN. The gene discussed is GREM1; the disease is diabetic kidney disease.